HVTN 141/ HPTN 105

Phase:Open Label
Principal Investigator(s):
Objective:A phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics and in vitro neutralization of VRC01.23LS, ePGDM1400v9-LS and ePGT121v1-LS alone and in combination in healthy, HIV-uninfected adult participantsAugust 2022 (AIDS 2022) update: Trial announced; Protocol currently in development. See June 2022 HPTN trial sheet for more information here*Not yet on ClinicalTrials.gov as of August 2022 Last updated August 10, 2022
Prevention Option(s):PrEP
Study Design:
Start Date
End Date
March 1, 2023
March 1, 2024
Age range: 18 Years ↔ any
Population:Cisgender Men, Cisgender Women